1
|
Papapoulos S, Bone H, Cosman F, Dempster DW, McClung MR, Nakamura T, Restrepo JFM, Bouxsein ML, Cohn D, de Papp A, Massaad R, Santora A. Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. J Bone Miner Res 2021; 36:1225-1234. [PMID: 33724542 DOI: 10.1002/jbmr.4284] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 03/01/2021] [Accepted: 03/08/2021] [Indexed: 12/23/2022]
Abstract
We prospectively assessed, with predefined criteria, the location and rates of all femur fractures (hip, subtrochanteric/femoral shaft [ST/FS], including atypical [AFF] and distal fractures) in women at increased fracture risk during treatment with the cathepsin K inhibitor, odanacatib (ODN), or placebo over 5 years in the Long-Term ODN Fracture Trial (LOFT and LOFT Extension [NCT00529373, EudraCT 2007-002693-66]). ODN was an investigational antiresorptive agent previously in development as an osteoporosis treatment that, unlike bisphosphonates, reduces bone formation only transiently. Women aged ≥65 years with a bone mineral density (BMD) T-score ≤-2.5 at the total hip (TH) or femoral neck (FN) or with a radiographic vertebral fracture and T-scores ≤-1.5 at the TH or FN were randomized (1:1) to receive ODN 50 mg/week or placebo. All patients received vitamin D3 (5600 IU/week) and calcium (total 1200 mg/d); the analysis included 16,071 women. Rates of all adjudicated low-energy femoral fractures were 0.38 versus 0.58/100 patient-years for ODN and placebo, respectively (hazard ratio [HR] = 0.65; 95% confidence interval [CI] 0.51-0.82; nominal p < .001), and for low-energy hip fractures were 0.29 versus 0.56/100 patient-years, respectively (HR = 0.52; 95% CI 0.40-0.67; p < .001). The cumulative incidence of combined hip and ST/FS or hip fractures alone in the ODN group was consistently lower than in the placebo group (1.93% versus 3.11% for combined fractures and 1.53% versus 3.03% for hip fractures at 5 years, respectively). However, low-energy ST/FS fractures were more frequent in ODN-treated women than in placebo-treated women (24 versus 6, respectively). Among these, 12 fractures were adjudicated as AFF in 10 patients treated with ODN (0.03/100 patient-years) compared with none in the 6 placebo-treated women (estimated difference 0.03; 95% CI 0.02-0.06). These results provide insight into possible pathogeneses of AFF, suggesting that the current criteria for diagnosing these fractures may need to be reconsidered. © 2021 American Society for Bone and Mineral Research (ASBMR)..
Collapse
Affiliation(s)
| | - Henry Bone
- Michigan Bone & Mineral Clinic, Detroit, MI, USA
| | | | | | - Michael R McClung
- Oregon Osteoporosis Center, Portland, OR, USA.,Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia
| | | | | | - Mary L Bouxsein
- Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, and Department of Orthopedic Surgery, Harvard Medical School, Boston, MA, USA
| | | | | | | | | |
Collapse
|
2
|
McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol 2019; 7:899-911. [PMID: 31676222 DOI: 10.1016/s2213-8587(19)30346-8] [Citation(s) in RCA: 95] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 09/09/2019] [Accepted: 09/09/2019] [Indexed: 12/28/2022]
Abstract
BACKGROUND Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining bone formation. Previous work has shown that odanacatib increases bone mineral density in postmenopausal women with low bone mass. We aimed to investigate the efficacy and safety of odanacatib to reduce fracture risk in postmenopausal women with osteoporosis. METHODS The Long-term Odanacatib Fracture Trial (LOFT) was a multicentre, randomised, double-blind, placebo-controlled, event-driven study at 388 outpatient clinics in 40 countries. Eligible participants were women aged at least 65 years who were postmenopausal for 5 years or more, with a femoral neck or total hip bone mineral density T-score between -2·5 and -4·0 if no previous radiographic vertebral fracture, or between -1·5 and -4·0 with a previous vertebral fracture. Women with a previous hip fracture, more than one vertebral fracture, or a T-score of less than -4·0 at the total hip or femoral neck were not eligible unless they were unable or unwilling to use approved osteoporosis treatment. Participants were randomly assigned (1:1) to either oral odanacatib (50 mg once per week) or matching placebo. Randomisation was done using an interactive voice recognition system after stratification for previous radiographic vertebral fracture, and treatment was masked to study participants, investigators and their staff, and sponsor personnel. If the study completed before 5 years of double-blind treatment, consenting participants could enrol in a double-blind extension study (LOFT Extension), continuing their original treatment assignment for up to 5 years from randomisation. Primary endpoints were incidence of vertebral fractures as assessed using radiographs collected at baseline, 6 and 12 months, yearly, and at final study visit in participants for whom evaluable radiograph images were available at baseline and at least one other timepoint, and hip and non-vertebral fractures adjudicated as being a result of osteoporosis as assessed by clinical history and radiograph. Safety was assessed in participants who received at least one dose of study drug. The adjudicated cardiovascular safety endpoints were a composite of cardiovascular death, myocardial infarction, or stroke, and new-onset atrial fibrillation or flutter. Individual cardiovascular endpoints and death were also assessed. LOFT and LOFT Extension are registered with ClinicalTrials.gov (number NCT00529373) and the European Clinical Trials Database (EudraCT number 2007-002693-66). FINDINGS Between Sept 14, 2007, and Nov 17, 2009, we randomly assigned 16 071 evaluable patients to treatment: 8043 to odanacatib and 8028 to placebo. After a median follow-up of 36·5 months (IQR 34·43-40·15) 4297 women assigned to odanacatib and 3960 assigned to placebo enrolled in LOFT Extension (total median follow-up 47·6 months, IQR 35·45-60·06). In LOFT, cumulative incidence of primary outcomes for odanacatib versus placebo were: radiographic vertebral fractures 3·7% (251/6770) versus 7·8% (542/6910), hazard ratio (HR) 0·46, 95% CI 0·40-0·53; hip fractures 0·8% (65/8043) versus 1·6% (125/8028), 0·53, 0·39-0·71; non-vertebral fractures 5·1% (412/8043) versus 6·7% (541/8028), 0·77, 0·68-0·87; all p<0·0001. Combined results from LOFT plus LOFT Extension for cumulative incidence of primary outcomes for odanacatib versus placebo were: radiographic vertebral fractures 4·9% (341/6909) versus 9·6% (675/7011), HR 0·48, 95% CI 0·42-0·55; hip fractures 1·1% (86/8043) versus 2·0% (162/8028), 0·52, 0·40-0·67; non-vertebral fractures 6·4% (512/8043) versus 8·4% (675/8028), 0·74, 0·66-0·83; all p<0·0001. In LOFT, the composite cardiovascular endpoint of cardiovascular death, myocardial infarction, or stroke occurred in 273 (3·4%) of 8043 patients in the odanacatib group versus 245 (3·1%) of 8028 in the placebo group (HR 1·12, 95% CI 0·95-1·34; p=0·18). New-onset atrial fibrillation or flutter occurred in 112 (1·4%) of 8043 patients in the odanacatib group versus 96 (1·2%) of 8028 in the placebo group (HR 1·18, 0·90-1·55; p=0·24). Odanacatib was associated with an increased risk of stroke (1·7% [136/8043] vs 1·3% [104/8028], HR 1·32, 1·02-1·70; p=0·034), but not myocardial infarction (0·7% [60/8043] vs 0·9% [74/8028], HR 0·82, 0·58-1·15; p=0·26). The HR for all-cause mortality was 1·13 (5·0% [401/8043] vs 4·4% [356/8028], 0·98-1·30; p=0·10). When data from LOFT Extension were included, the composite of cardiovascular death, myocardial infarction, or stroke occurred in significantly more patients in the odanacatib group than in the placebo group (401 [5·0%] of 8043 vs 343 [4·3%] of 8028, HR 1·17, 1·02-1·36; p=0·029, as did stroke (2·3% [187/8043] vs 1·7% [137/8028], HR 1·37, 1·10-1·71; p=0·0051). INTERPRETATION Odanacatib reduced the risk of fracture, but was associated with an increased risk of cardiovascular events, specifically stroke, in postmenopausal women with osteoporosis. Based on the overall balance between benefit and risk, the study's sponsor decided that they would no longer pursue development of odanacatib for treatment of osteoporosis. FUNDING Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA.
Collapse
Affiliation(s)
- Michael R McClung
- Oregon Osteoporosis Center, Portland, OR, USA; Mary MacKillop Center for Health Research, Australian Catholic Unversity, Melbourne, VIC, Australia
| | - Michelle L O'Donoghue
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | | | - Henry Bone
- Michigan Bone and Mineral Clinic, Detroit, MI, USA
| | | | - Kenneth G Saag
- University of Alabama at Birmingham, Birmingham, AL, USA
| | - Ian R Reid
- University of Auckland, Auckland, New Zealand
| | - Douglas P Kiel
- Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, USA
| | - Ilaria Cavallari
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | - Marc P Bonaca
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | - Stephen D Wiviott
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | | | - Xu Ling
- Peking Union Medical College, Dongcheng, Beijing, China
| | - Kurt Lippuner
- Bern University Hospital, University of Bern, Bern, Switzerland
| | | | - Jean-Yves Reginster
- Department of Public Health, Epidemiology and Health Economics and WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, University of Liège, Liège, Belgium
| | | | - Christian Roux
- Paris Descartes University, Cochin Hospital, Paris, France
| | - José Zanchetta
- Institute of Metabolic Research, Buenos Aires, Argentina
| | | | - Jeong-Gun Park
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | - KyungAh Im
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | - Abby Cange
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | - Laura T Grip
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Marc S Sabatine
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
| | | |
Collapse
|
3
|
Mannstadt M, Clarke BL, Bilezikian JP, Bone H, Denham D, Levine MA, Peacock M, Rothman J, Shoback DM, Warren ML, Watts NB, Lee HM, Sherry N, Vokes TJ. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab 2019; 104:5136-5147. [PMID: 31369089 PMCID: PMC6760337 DOI: 10.1210/jc.2019-01010] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Accepted: 07/26/2019] [Indexed: 12/12/2022]
Abstract
CONTEXT Conventional hypoparathyroidism treatment with oral calcium and active vitamin D is aimed at correcting hypocalcemia but does not address other physiologic defects caused by PTH deficiency. OBJECTIVE To evaluate long-term safety and tolerability of recombinant human PTH (1-84) [rhPTH(1-84)]. DESIGN Open-label extension study; 5-year interim analysis. SETTING 12 US centers. PATIENTS Adults (N = 49) with chronic hypoparathyroidism. INTERVENTION(S) rhPTH(1-84) 25 or 50 µg/d initially, with 25-µg adjustments permitted to a 100 µg/d maximum. MAIN OUTCOME MEASURE(S) Safety parameters; composite efficacy outcome was the proportion of patients with ≥50% reduction in oral calcium (or ≤500 mg/d) and calcitriol (or ≤0.25 µg/d) doses, and albumin-corrected serum calcium normalized or maintained compared with baseline, not exceeding upper limit of normal. RESULTS Forty patients completed 60 months of treatment. Mean albumin-corrected serum calcium levels remained between 8.2 and 8.7 mg/dL. Between baseline and month 60, levels ± SD of urinary calcium, serum phosphorus, and calcium-phosphorus product decreased by 101.2 ± 236.24 mg/24 hours, 1.0 ± 0.78 mg/dL, and 8.5 ± 8.29 mg2/dL2, respectively. Serum creatinine level and estimated glomerular filtration rate were unchanged. Treatment-emergent adverse events (AEs) were reported in 48 patients (98.0%; hypocalcemia, 36.7%; muscle spasms, 32.7%; paresthesia, 30.6%; sinusitis, 30.6%; nausea, 30.6%) and serious AEs in 13 (26.5%). At month 60, 28 patients (70.0%) achieved the composite efficacy outcome. Bone turnover markers increased, peaked at ∼12 months, and then declined to values that remained above baseline. CONCLUSION Treatment with rhPTH(1-84) for 5 years demonstrated a safety profile consistent with previous studies and improved key biochemical parameters.
Collapse
Affiliation(s)
- Michael Mannstadt
- Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
- Correspondence and Reprint Requests: Michael Mannstadt, MD, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Thier-1123, Boston, Massachusetts 02114. E-mail:
| | - Bart L Clarke
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota
| | - John P Bilezikian
- Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York
| | - Henry Bone
- Michigan Bone and Mineral Clinic, PC, Detroit, Michigan
| | | | - Michael A Levine
- Division of Endocrinology and Diabetes and Center for Bone Health, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Munro Peacock
- Department of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana
| | - Jeffrey Rothman
- University Physicians Group – Research Division, Staten Island, New York
| | - Dolores M Shoback
- Endocrine Research Unit, Department of Medicine, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, California
| | - Mark L Warren
- Endocrinology and Metabolism, Physicians East, Greenville, North Carolina
| | - Nelson B Watts
- Osteoporosis and Bone Health Services, Mercy Health, Cincinnati, Ohio
| | - Hak-Myung Lee
- Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies, Lexington, Massachusetts
| | - Nicole Sherry
- Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies, Cambridge, Massachusetts
| | - Tamara J Vokes
- Section of Endocrinology, University of Chicago Medicine, Chicago, Illinois
| |
Collapse
|
4
|
Bilezikian J, Bone H, Clarke B, Denham D, Lee HM, Levine M, Mannstadt M, Peacock M, Rothman J, Sherry N, Shoback D, Vokes T, Warren M, Watts N. OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study. J Endocr Soc 2019. [PMCID: PMC6554941 DOI: 10.1210/js.2019-or30-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
RACE is an open-label study that assessed the long-term safety and efficacy of recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) for the treatment of hypoparathyroidism in adults (ClinicalTrials.gov identifier NCT01297309). Patients initially received 25 or 50 µg/day of rhPTH(1-84) subcutaneously, once daily, with stepwise dose adjustments of 25 µg (up or down) to a maximum of 100 µg/day. rhPTH(1-84) could be titrated and oral calcium (Ca) and calcitriol doses adjusted at any time during the study to maintain albumin-corrected serum Ca levels in the target range of 8.0-9.0 mg/dL. A composite efficacy endpoint was the proportion of patients who achieved at least a 50% reduction from baseline (BL) in oral Ca dose (or Ca ≤500 mg/day) and at least a 50% reduction from BL in calcitriol dose (or calcitriol ≤0.25 µg/day), while normalizing or maintaining albumin-corrected serum Ca compared with BL value and not exceeding the upper limit of normal for the central laboratory. Here, we present 6-year safety and efficacy data with descriptive summary statistics (mean ± SD). The study cohort consisted of 49 patients enrolled at 12 US centers (mean age, 48.1±9.78 years; 81.6% female); data from 34 patients (69.4%) who completed 72 months (M72) of treatment with rhPTH(1-84) as of July 17, 2018 are presented here. Oral Ca and calcitriol doses were reduced by 40.4% and 72.2% at M72, respectively, and albumin-corrected serum Ca levels were maintained within the target range (BL, 8.4±0.70 mg/dL; M72, 8.4±0.68 mg/dL). At M72, 22 of 34 patients (64.7%) achieved the composite efficacy endpoint. Urinary Ca excretion declined from above-normal at BL to within the normal range (BL, 356.7±200.37 mg/24 h; M72, 213.2±128.82 mg/24 h). Mean serum creatinine levels remained stable (BL, 1.0±0.21 mg/dL; M72, 0.9±0.21 mg/dL), as did estimated glomerular filtration rate (eGFR; BL, 77.7±17.67 mL/min/1.73 m2; M72, 79.4±18.39 mL/min/1.73 m2). Serum phosphorus levels declined from above-normal at BL to within normal range (BL, 4.8±0.58 mg/dL; M72, 4.0±0.62 mg/dL); calcium-phosphorus product levels also declined (BL, 42.1±6.35 mg2/dL2; M72, 33.7±5.01 mg2/dL2). Treatment-emergent adverse events and treatment-emergent serious adverse events were reported in 98.0% and 26.5% of patients, respectively; no new safety concerns were identified. Continuous use of rhPTH(1-84) over 6 years resulted in a favorable safety profile, was effective, and improved key measurements of mineral homeostasis, notably normalization of urinary calcium. Disclosures: All of the authors disclose a relationship with Shire: advisory board member, JPB, MAL, MM, DMS, TJV; consultant, JPB, BLC, MAL, MM, DMS, TJV; grant recipient, JPB, DD, MM, MP, DMS, MLW; employee, H-ML, NS; research investigator, JPB, HB, JR, DMS, TJV, MLW, NBW; speaker, JPB, HB, MLW, NBW. Funding: Shire
Collapse
Affiliation(s)
- John Bilezikian
- Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, United States
| | - Henry Bone
- Michigan Bone and Mineral Clinic, PC, Detroit, MI, United States
| | - Bart Clarke
- Div of Endo and Metab, Mayo Clinic Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Rochester, MN, United States
| | - Douglas Denham
- Clinical Trials of Texas, Inc., San Antonio, TX, United States
| | - Hak-Myung Lee
- Shire Human Genetic Therapies, Inc., Lexington, MA, United States
| | - Michael Levine
- Division of Endocrinology and Diabetes, Division of Endocrinology and Diabetes and Center for Bone Health, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
| | - Michael Mannstadt
- Endocrine Unit, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | - Munro Peacock
- Department of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Jeffrey Rothman
- University Physicians Group-Endocrine Division, University Physicians Group – Research Division, Staten Island, NY, United States
| | - Nicole Sherry
- Shire Human Genetic Therapies, Inc., Cambridge, MA, United States
| | - Dolores Shoback
- Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, Department of Medicine, University of California, San Francisco, CA, United States
| | - Tamara Vokes
- Dept of Int Med/Endo, Section of Endocrinology, University of Chicago Medicine, Chicago, IL, United States
| | - Mark Warren
- Endocrinology and Metabolism, Physicians East, PA, Greenville, NC, United States
| | - Nelson Watts
- Osteoporosis and Bone Health Services, Mercy Health, Cincinnati, OH, United States
| |
Collapse
|
5
|
Bone H, Brandi M, Brown J, Chapurlat R, Cummings S, Czerwinski E, Fahrleitner-Pammer A, Kendler D, Lippuner K, Reginster JY, Vittinghoff E, Daizadeh N, Wang A, Dakin P, Wagman R, Papapoulos S. OP0306 Ten Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Results from The Freedom Extension Trial. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Tóth M. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol 2015; 172:527-35. [PMID: 25637076 PMCID: PMC5729741 DOI: 10.1530/eje-14-0877] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
OBJECTIVE Primary hyperparathyroidism (PHPT) is diagnosed by the presence of hypercalcemia and elevated or nonsuppressed parathyroid hormone (PTH) levels. Although surgery is usually curative, some individuals fail or are unable or unwilling to undergo parathyroidectomy. In such individuals, targeted medical therapy may be of value. Cinacalcet normalized calcium level and lowered PTH in patients with PHPT in several phase 2 and open-label studies. We compared cinacalcet and placebo in subjects with PHPT unable to undergo parathyroidectomy. DESIGN Phase 3, double-blind, multi centere, randomized, placebo-controlled study. METHODS Sixty-seven subjects (78% women) with moderate PHPT were randomized (1:1) to cinacalcet or placebo for ≤28 weeks. MAIN OUTCOME MEASURE Achievement of a normal mean corrected total serum calcium concentration of ≤10.3 mg/dl (2.575 mmol/l). RESULTS Baseline median (quartile 1 (Q1), Q3) serum PTH was 164.0 (131.0, 211.0) pg/ml and mean (s.d.) serum Ca was 11.77 (0.46) mg/dl. Serum Ca normalized (≤10.3 mg/dl) in 75.8% of cinacalcet- vs 0% of placebo-treated subjects (P<0.001). Corrected serum Ca decreased by ≥1.0 mg/dl from baseline in 84.8% of cinacalcet- vs 5.9% of placebo-treated subjects (P<0.001). Least squares mean (s.e.m.) plasma PTH change from baseline was -23.80% (4.18%) (cinacalcet) vs -1.01% (4.05%) (placebo) (P<0.001). Similar numbers of subjects in the cinacalcet and placebo groups reported adverse events (AEs) (27 vs 20) and serious AEs (three vs four). Most commonly reported AEs were nausea and muscle spasms. CONCLUSIONS These results demonstrate that cinacalcet normalizes serum calcium in this PHPT population and appears to be well tolerated.
Collapse
Affiliation(s)
- Aliya Khan
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - John Bilezikian
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - Henry Bone
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - Andrey Gurevich
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - Peter Lakatos
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - Waldemar Misiorowski
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - Liudmila Rozhinskaya
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - Marie-Louise Trotman
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - Miklós Tóth
- Divisions of Endocrinology and GeriatricsMcMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8College of Physicians and SurgeonsColumbia University, New York, New York, USAMichigan Bone and Mineral ClinicDetroit, Michigan, USAAmgen (Europe) GmbHZug, Switzerland1st Department of MedicineSemmelweis University Medical School, Budapest, HungaryDepartment of EndocrinologyMedical Centre of Postgraduate Education, Warsaw, PolandEndocrinology Research CentreMoscow, RussiaAmgenInc., Thousand Oaks, California, USA2nd Department of MedicineSemmelweis University, Budapest, Hungary
| |
Collapse
|
7
|
Binkley N, Bone H, Gilligan JP, Krause DS. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Osteoporos Int 2014; 25:2649-56. [PMID: 25027109 PMCID: PMC4203997 DOI: 10.1007/s00198-014-2796-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Accepted: 06/25/2014] [Indexed: 01/27/2023]
Abstract
UNLABELLED The effect of an investigational oral calcitonin tablet upon bone mineral density (BMD) of the spine was investigated in postmenopausal women with low bone mass and at increased risk of fracture. Compared to placebo, calcitonin tablets increased lumbar spine BMD. This agent may provide an additional choice for patients. INTRODUCTION An investigational oral salmon calcitonin preparation was previously shown to increase lumbar spine BMD in postmenopausal women with osteoporosis. Our objective was to evaluate the use of this agent in postmenopausal women with low bone mass and at increased fracture risk but not meeting BMD criteria for osteoporosis. METHODS Treatment-naïve women were randomized to receive oral recombinant salmon calcitonin tablets or placebo once daily for 1 year. Dual-energy X-ray absorptiometry was performed at baseline and at study weeks 28 and 54. CTx-1, a bone resorption marker, was obtained at the same time points. Subjects returned periodically for tolerability assessment and adverse event (AE) recording. RESULTS One hundred twenty-nine women in the USA were randomized, 86 to calcitonin and 43 to placebo. Calcitonin recipients experienced a significant increase from baseline in lumbar spine BMD; the difference compared with placebo was significant. Dosing at bedtime or with dinner was equally effective. CTx-1 was suppressed in calcitonin recipients but not in placebo subjects. Gastrointestinal AEs were common, but the overall safety profile was comparable between groups. CONCLUSIONS Oral calcitonin may provide a useful therapeutic alternative for some women with low bone mass.
Collapse
Affiliation(s)
- N Binkley
- University of Wisconsin Osteoporosis Clinical Center and Research Program, Madison, WI, USA,
| | | | | | | |
Collapse
|
8
|
Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Dasilva C, Rosenberg E, Leung A. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 2012; 27:2251-8. [PMID: 22777865 DOI: 10.1002/jbmr.1695] [Citation(s) in RCA: 129] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that is highly expressed by osteoclasts. In this 2-year, phase 2, dose-ranging trial, postmenopausal women with bone mineral density (BMD) T-scores -2.0 to -3.5 at spine or hip were randomized to weekly placebo or ODN 3, 10, 25, or 50 mg plus vitamin D(3) and calcium. Prespecified trial-extensions continued through 5 years. In year 3, all women were re-randomized to ODN 50 mg or placebo. For years 4 and 5, women who received placebo or ODN 3 mg in years 1 and 2 and placebo in year 3 received ODN 50 mg; others continued year 3 treatments. Endpoints included lumbar spine (primary), hip, 1/3 radius, and total body BMD; markers of bone metabolism; and safety. Women in the year 4 to 5 extension receiving placebo (n = 41) or ODN 50 mg (n = 100) had similar baseline characteristics. For women who received ODN (10-50 mg) for 5 years, spine and hip BMD increased over time. With ODN 50 mg continually for 5 years (n = 13), mean lumbar spine BMD percent change from baseline (95% confidence interval [CI]) was 11.9% (7.2% to 16.5%) versus -0.4% (-3.1% to 2.3%) for women who were switched from ODN 50 mg to placebo after 2 years (n = 14). In pooled results of women receiving continuous ODN (10-50 mg, n = 26-29), year 5 geometric mean percent changes from baseline in bone resorption markers cross-linked N-telopeptide of type I collagen (NTX)/creatinine and cross-linked C-telopeptide (CTX) were approximately -55%, but near baseline for bone formation markers bone-specific alkaline phosphatase (BSAP) and amino-terminal propeptide of type I procollagen (P1NP). In women switched from ODN 10 to 50 mg to placebo after 2 years (n = 25), bone turnover markers were near baseline. In summary, women receiving combinations of ODN (10-50 mg) for 5 years had gains in spine and hip BMD and showed larger reductions in bone resorption than bone formation markers. Discontinuation of ODN resulted in reversal of treatment effects. Treatment with ODN for up to 5 years was generally well-tolerated.
Collapse
Affiliation(s)
- Bente Langdahl
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Watts N, Binkley N, Bone H, Gilchrist N, Langdahl B, Resch H, Denker A. Treatment With the Cathepsin K Inhibitor Odanacatib in Postmenopausal Women With Low BMD: 5 Year Results of a Phase 2 Trial. J Clin Densitom 2012. [DOI: 10.1016/j.jocd.2012.08.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Abstract
Future directions in osteoporosis treatment will include development of medications with increasingly precise mechanistic targets, including the RANK-ligand pathway, cathepsin K inhibition, and Wnt signaling manipulation. More gains are likely with anabolics and newer antiresorptives that cause little or no suppression of formation. Optimal treatment of osteoporosis may require coordination of anabolic and antiresorptive treatment, following stimulation of bone formation with consolidation and long-term maintenance. Some well-established drugs may be useful in such regimens. We can also anticipate emphasis on cost containment using currently available drugs, especially as they become generic. Effective implementation and treatment continuity will be important themes.
Collapse
Affiliation(s)
- Henry Bone
- Section of Endocrinology and Metabolism, Michigan Bone and Mineral Clinic, St. John Hospital and Medical Center, 22201 Moross Road, Detroit, MI 48236, USA.
| |
Collapse
|
11
|
Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010; 25:2256-65. [PMID: 20533525 DOI: 10.1002/jbmr.149] [Citation(s) in RCA: 157] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Denosumab, a human monoclonal antibody against RANKL, reversibly inhibits osteoclast-mediated bone resorption and has been developed for use in osteoporosis. Its effects on bone histomorphometry have not been described previously. Iliac crest bone biopsies were collected at 24 and/or 36 months from osteoporotic postmenopausal women in the FREEDOM study (45 women receiving placebo and 47 denosumab) and at 12 months from postmenopausal women previously treated with alendronate in the STAND study (21 continuing alendronate and 15 changed to denosumab at trial entry). Qualitative histologic evaluation of biopsies was unremarkable. In the FREEDOM study, median eroded surface was reduced by more than 80% and osteoclasts were absent from more than 50% of biopsies in the denosumab group. Double labeling in trabecular bone was observed in 94% of placebo bones and in 19% of those treated with denosumab. Median bone-formation rate was reduced by 97%. Among denosumab-treated subjects, those with double labels and those with absent labels had similar levels of biochemical markers of bone turnover. In the STAND trial, indices of bone turnover tended to be lower in the denosumab group than in the alendronate group. Double labeling in trabecular bone was seen in 20% of the denosumab biopsies and in 90% of the alendronate samples. Denosumab markedly reduces bone turnover and also reduces fracture numbers. Longer follow-up is necessary to determine how long such low turnover is safe.
Collapse
Affiliation(s)
- Ian R Reid
- Department of Medicine, University of Auckland, Auckland, New Zealand.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Harel Z, Wolter K, Gold MA, Cromer B, Bruner A, Stager M, Bachrach L, Hertweck P, Nelson A, Nelson D, Coupey S, Johnson CC, Burkman R, Bone H. Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study. J Pediatr Adolesc Gynecol 2010; 23:209-14. [PMID: 20471875 DOI: 10.1016/j.jpag.2009.11.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2009] [Revised: 11/05/2009] [Accepted: 11/06/2009] [Indexed: 11/17/2022]
Abstract
STUDY OBJECTIVE To examine vitamin D and parathormone (PTH) levels in adolescents who experienced substantial bone mineral density (BMD) loss during depot medroxyprogesterone acetate (DMPA) use. DESIGN A non-randomized, multi-center study, during which DMPA was administered every 12 weeks and evaluation of lumbar spine and hip BMD by dual-energy X-ray absorptiometry (DXA) was conducted every 6 months. A blood sample for vitamin D and PTH measurements was obtained from adolescents who experienced >5% BMD loss. Vitamin D deficiency was defined as 25-hydroxyvitamin D (25OHD) level of <20 ng/mL, insufficiency as 25OHD level of 20-30 ng/mL, and sufficiency as 25OHD level of >30 ng/mL. RESULTS Evaluation of vitamin D and PTH was carried out in 15 participants who experienced BMD loss of > or = 5% during DMPA use. At initiation of DMPA, participants had mean (+SE) age 17+1 years, gynecologic age 61+4 months, and body mass index 24+1.5 kg/m2. Racial/ethnic distribution was: Caucasian--7 girls, Hispanic--4 girls, African-American--3 girls, and other--1 girl. Six participants had BMD loss of >5% after 2 DMPA injections, five after 3 injections, one after 5 injections, one after 8 injections, one after 10 injections, and one after 13 injections. Only one girl (7%) had sufficient vitamin D. The other participants had vitamin D insufficiency (50%) or deficiency (43%). Participants' mean (+SE) PTH was 22+4 pg/mL (reference range 7-53 pg/mL), and mean (+SE) 1,25-dihydroxyvitamin D was 56+5 pg/mL (reference range 22-67 pg/mL). CONCLUSIONS Inadequate vitamin D status was evident among the majority of female adolescents who experienced a substantial BMD loss while using DMPA.
Collapse
Affiliation(s)
- Z Harel
- Division of Adolescent Medicine, Hasbro Children's Hospital and Brown University, Providence, RI 02903, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, Stager M, Brown R, Bruner A, Coupey S, Hertweck P, Bone H, Wolter K, Nelson A, Marshall S, Bachrach LK. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2009; 81:281-91. [PMID: 20227543 DOI: 10.1016/j.contraception.2009.11.003] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Revised: 11/05/2009] [Accepted: 11/09/2009] [Indexed: 11/15/2022]
Abstract
BACKGROUND Depot medroxyprogesterone acetate (DMPA) is a highly effective progestin-only contraceptive that is widely used by adolescents. We investigated bone mineral density (BMD) changes in female adolescents during and following use of this method. STUDY DESIGN A multicenter, prospective, non-randomized observational study in 98 healthy female adolescents aged 12-18 years who initiated DMPA intramuscular injections for contraception and provided BMD data for up to 240 weeks while receiving DMPA and for up to 300 weeks after DMPA cessation. BMD at the lumbar spine (LS), total hip (TH) and femoral neck (FN) was assessed by dual-energy X-ray absorptiometry. A mixed model analysis of variance was used to examine BMD changes. RESULTS At the time of their final DMPA injection, participants had mean BMD declines from baseline of 2.7% (LS), 4.1% (TH) and 3.9% (FN) (p<.001 at all three sites). Within 60 weeks of discontinuation of DMPA, mean LS BMD had returned to baseline levels, and 240 weeks after DMPA discontinuation, the mean LS BMD was 4.7% above baseline. Mean TH and FN BMD values recovered to baseline values more slowly: 240 weeks and 180 weeks, respectively, after the last DMPA injection. CONCLUSIONS BMD loss in female adolescents receiving DMPA for contraception is substantially or fully reversible in most girls following discontinuation of DMPA, with faster recovery at the LS than at the hip.
Collapse
Affiliation(s)
- Zeev Harel
- Division of Adolescent Medicine, Hasbro Children's Hospital and Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Smith MR, Ellis G, Saad F, Tammela T, Bone H, Egerdie B, Ke C, Jun S, Dansey R, Goessl C. Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9520] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9520 Background: Hormone ablation therapies, including adjuvant aromatase inhibitor (AI) therapy and androgen deprivation therapy (ADT), improve recurrence-free survival in patients (pts) with BC and PC, respectively. However, these treatments increase bone resorption, leading to bone loss and fractures. RANKL is a key mediator of osteoclast-mediated bone resorption. In this 24 month (mo) comparison, we investigated the effects of denosumab, a fully human monoclonal antibody against RANKL, on preserving BMD across both populations. Methods: Two trials were conducted: a 24-mo BC study and a 36-mo PC study. Postmenopausal women with low BMD receiving AI therapy for nonmetastatic BC and men receiving ADT for nonmetastatic PC (with low BMD or history of osteoporotic fracture if < 70 yrs) were randomized to receive placebo or denosumab 60mg subcutaneously every 6 mos. All pts in both studies were prescribed calcium and vitamin D supplements. The primary endpoint was % change from baseline in lumbar spine (LS) BMD at 12 mos for the BC study and at 24 mos for the PC study. Herein, we present changes in BMD at 24 mos at LS, total hip (TH), and 1/3 radius from both studies. Power calculations were based on enrollment of at least 208 patients in the BC study (for primary endpoint only) and 1226 in the PC study (for primary and key secondary endpoints). The actual numbers randomized were 252 and 1468, respectively. Results: Denosumab increased BMD of the LS, TH, and 1/3 radius compared with placebo at 24 mos in both pt populations ( Table ). In both studies, differences between denosumab and placebo at each skeletal site were consistent, and the effects of denosumab were statistically significantly different from placebo as early as 1 month at the LS in both studies. The overall safety profile was similar to placebo in each study. Conclusions: Denosumab consistently increased BMD at all 3 skeletal sites compared with placebo in both women with BC undergoing AI therapy and in men with PC undergoing ADT. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- M. R. Smith
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - G. Ellis
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - F. Saad
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - T. Tammela
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - H. Bone
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - B. Egerdie
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - C. Ke
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - S. Jun
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - R. Dansey
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - C. Goessl
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| |
Collapse
|
15
|
Harel Z, Gold M, Cromer B, Bruner A, Stager M, Bachrach L, Wolter K, Reid C, Hertweck P, Nelson A, Nelson D, Coupey S, Johnson C, Burkman R, Bone H. Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markers. J Adolesc Health 2007; 40:44-53. [PMID: 17185205 DOI: 10.1016/j.jadohealth.2006.08.013] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2006] [Revised: 06/01/2006] [Accepted: 08/16/2006] [Indexed: 11/26/2022]
Abstract
PURPOSE During adolescence, bone formation prevails over resorption, resulting in accumulation of 40% of peak bone mass throughout this time period. Although multiple studies have explored bone mass accrual during the early stages of puberty, less is known about factors that may influence bone accrual during later years of adolescence. In the present cross-sectional study we examined relationships among bone mineral density (BMD) and demographic factors, behavioral variables, and bone metabolism markers in postmenarchal adolescent girls. METHODS The population was comprised of 389 healthy postmenarchal adolescent girls aged 11-18 years, who were recruited into a prospective study of the effect of depot medroxyprogesterone acetate (DMPA) on bone health in adolescents. At the baseline visit, investigators collected demographic, reproductive health, and lifestyle data, and performed a complete physical examination. Body mass index (BMI) was calculated. Before study initiation, BMD at the lumbar spine, total hip, and femoral neck was measured by dual-energy X-ray absorptiometry (DXA), and markers of bone metabolism (serum bone-specific alkaline phosphatase [BAP], serum osteocalcin, and urinary N-telopeptide [uNTX]) were measured. The baseline data from this study were analyzed to evaluate possible correlates of BMD in postmenarchal adolescent girls. Potential associations between BMD values and other parameters were assessed by analysis of variance and Pearson's correlation coefficient. RESULTS Participants enrolled in the study had a mean (+/- SD) chronological age of 14.9 +/-1.7 years (range 11-18), mean gynecologic age of 39.9 +/-23.0 months (range 1-120) postmenarche, and mean BMI of 23.5 +/-4.6 kg/m(2) (range 16.0-42.2). Racial/ethnic distribution was 46% African American, 35% Caucasian, and 19% other races; 9% had previously been pregnant. Positive correlations were observed between lumbar spine BMD and chronological age (r = .301, p < .0001), gynecologic age (r = .349, p < .0001), and BMI (r = .371, p < .0001). Total hip and femoral neck BMD values were significantly higher (p < .05 and p < .05, respectively) in African American participants compared with non-African American participants. Previous history of pregnancy was significantly associated with a lower BMD at the lumbar spine (p < .0001) and the total hip (p < .01) when compared with the BMD of adolescents who had never been pregnant. Cigarette smoking and alcohol use were not associated with significant differences in BMD. Negative correlations were observed between gynecologic age and the levels of BAP (r = -.564, p < .0001), osteocalcin (r = -.349, p < .0001), and uNTX (r = -.281, p < .0001), and between lumbar spine BMD and BAP (r = -.363, p < .0001), osteocalcin (r = -.129, p < .05), and uNTX (r = -.202, p < .001) levels. CONCLUSIONS Our data demonstrate that chronological age, gynecologic age, race/ethnicity, BMI, and previous history of pregnancy are markedly associated with BMD in postmenarchal adolescent girls. Bone accretion in the postmenarchal years continues in the face of a slowdown in bone turnover during this time period.
Collapse
Affiliation(s)
- Zeev Harel
- Hasbro Children's Hospital and Brown University, Providence, Rhode Island 02903, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Reinhart K, Brunkhorst F, Bone H, Gerlach H, Gründling M, Kreymann G, Kujath P, Marggraf G, Mayer K, Meier-Hellmann A, Peckelsen C, Putensen C, Quintel M, Ragaller M, Rossaint R, Stüber F, Weiler N, Welte T, Werdan K. [Diagnosis and therapy of sepsis. Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine]. Internist (Berl) 2006; 47:356, 358-60, 362-8, passim. [PMID: 16532281 DOI: 10.1007/s00108-006-1595-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
A recent survey conducted by the publicly funded Competence Network Sepsis (SepNet) reveals that severe sepsis and/or septic shock occurs in 75,000 inhabitants (110 out of 100,000) and sepsis in 79,000 inhabitants (116 out of 100,000) in Germany annually. This illness is responsible for approximately 60,000 deaths and ranges as the third most frequent cause of death after acute myocardial infarction. Direct costs for the intensive care of patients with severe sepsis alone amount to approximately 1.77 billion euros, which means that about 30% of the budget in intensive care is used to treat severe sepsis. However, until now German guidelines for the diagnosis and therapy of severe sepsis did not exist. Therefore, the German Sepsis Society initiated the development of guidelines which are based on international recommendations by the International Sepsis Forum (ISF) and the Surviving Sepsis Campaign (SSC) and take into account the structure and organization of the German health care system. Priority was given to the following guideline topics: a) diagnosis, b) prevention, c) causative therapy, d) supportive therapy, e) adjunctive therapy. The guidelines development process was carefully planned and strictly adhered to the requirements of the Working Group of Scientific Medical Societies (AWMF).
Collapse
Affiliation(s)
- K Reinhart
- Klinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum der Friedrich-Schiller-Universität Jena
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Reinhart K, Brunkhorst F, Bone H, Gerlach H, Gründling M, Kreymann G, Kujath P, Marggraf G, Mayer K, Meier-Hellmann A, Peckelsen C, Putensen C, Quintel M, Ragaller M, Rossaint R, Stüber F, Weiler N, Welte T, Werdan K. [Diagnosis and therapy of sepsis: guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine]. Anaesthesist 2006; 55 Suppl 1:43-56. [PMID: 17051663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
A recent survey conducted by the publicly funded Competence Network Sepsis (SepNet) reveals that severe sepsis and/or septic shock occurs in 75,000 inhabitants (110 out of 100,000) and sepsis in 79,000 inhabitants (116 out of 100,000) in Germany annually. This illness is responsible for approximately 60,000 deaths and ranges as the third most frequent cause of death after acute myocardial infarction. Direct costs for the intensive care of patients with severe sepsis alone amount to approximately 1.77 billion euros, which means that about 30% of the budget in intensive care is used to treat severe sepsis. However, until now German guidelines for the diagnosis and therapy of severe sepsis did not exist. Therefore, the German Sepsis Society initiated the development of guidelines which are based on international recommendations by the International Sepsis Forum (ISF) and the Surviving Sepsis Campaign (SSC) and take into account the structure and organization of the German health care system. Priority was given to the following guideline topics: a) diagnosis, b) prevention, c) causative therapy, d) supportive therapy, e) adjunctive therapy. The guidelines development process was carefully planned and strictly adhered to the requirements of the Working Group of Scientific Medical Societies (AWMF).
Collapse
Affiliation(s)
- K Reinhart
- Deutsche Sepsis-Gesellschaft e V c/o Universitatsklinikum Jena, Erlanger Allee 101, 07747 Jena
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Steele C, Steel D, Bone H, McParland L, Green L, Fraser S. Managing 'suspicious glaucomatous discs' identified during digital-photography-based diabetic retinopathy screening. Ophthalmic Physiol Opt 2006; 26:19-25. [PMID: 16390478 DOI: 10.1111/j.1475-1313.2005.00361.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
PURPOSE An audit to demonstrate the outcome of patients identified with suspicious glaucomatous discs within a digital-photography-based diabetic retinopathy screening programme. METHODS Primary care based digital photographic screening was performed utilising mydriasis and two-field digital photography for all patients with diabetes. Patients identified with discs suspicious of glaucomatous optic neuropathy (GON) were initially referred to an accredited community-based optometrist for further assessment. Some patients were then referred to secondary care where appropriate. RESULTS From 1st April 2002 to 31st March 2003 a total of 3868 patients were screened for diabetic retinopathy. This audit revealed that 55 subjects were identified by retinal screeners as having discs suspicious of glaucoma. A total of 29 were already under glaucoma clinic review. A total of 23/26 remaining were referred for an assessment by an accredited optometrist. Of these 13 were normal, 6 were referred to secondary care and 4 failed to attend. The three remaining were referred directly to secondary care. CONCLUSIONS All nine referrals to secondary care were deemed appropriate by a glaucoma specialist. This suggests that the system described does not lead to over-referral of suspicious discs - although the issue of how many glaucomatous discs are missed during screening (false negatives) will only be answered in the longer term.
Collapse
|
19
|
Luckey M, Kagan R, Greenspan S, Bone H, Kiel RDP, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*. Menopause 2004; 11:405-15. [PMID: 15243278 DOI: 10.1097/01.gme.0000119981.77837.1f] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To compare the efficacy and tolerability of once-weekly (OW) alendronate (ALN) 70 mg and raloxifene (RLX) 60 mg daily in the treatment of postmenopausal osteoporosis. DESIGN This 12-month, randomized, double-blind study enrolled 456 postmenopausal women with osteoporosis (223 ALN, 233 RLX) at 52 sites in the United States. Efficacy measurements included lumbar spine (LS), total hip, and trochanter bone mineral density (BMD) at 6 and 12 months, biochemical markers of bone turnover, and percent of women who maintained or gained BMD in response to treatment. The primary endpoint was percent change from baseline in LS BMD at 12 months. Adverse experiences were recorded to assess treatment safety and tolerability. RESULTS Over 12 months, OW ALN produced a significantly greater increase in LS BMD (4.4%, P < 0.001) than RLX (1.9%). The percentage of women with > or = 0% increase in LS BMD (ALN, 94%; RLX, 75%; P < 0.001) and > or =3% increase in LS BMD (ALN, 66%; RLX, 38%; P < 0.001) were significantly greater with ALN than RLX. Total hip and trochanter BMD increases were also significantly greater (P < or =0.001) with ALN. Greater (P < 0.001) reductions in N-telopeptide of type I collagen and bone-specific alkaline phosphatase were achieved with ALN compared with RLX at 6 and 12 months. No significant differences in the incidence of upper gastrointestinal or vasomotor adverse experiences were seen. CONCLUSION ALN 70 mg OW produced significantly greater increases in spine and hip BMD and greater reductions in markers of bone turnover than RLX over 12 months. A greater percentage of women maintained or gained BMD on ALN than RLX. Both medications had similar safety and tolerability profiles.
Collapse
Affiliation(s)
- Marjorie Luckey
- St. Barnabas Osteoporosis & Metabolic Bone Disease Center, Livingston, NJ, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
The advent of effective agents for the treatment of osteoporosis has led to the view that placebo-controlled trials to test new agents for efficacy are no longer appropriate since proven treatments are available. In this review we argue that, if new agents are to be developed, there is still a place for the placebo-controlled trial. A move to studies of equivalence or non-inferiority raises more problems than it resolves.
Collapse
Affiliation(s)
- J A Kanis
- WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Bone H, Williams NA. Antigen-receptor cross-linking and lipopolysaccharide trigger distinct phosphoinositide 3-kinase-dependent pathways to NF-kappa B activation in primary B cells. Int Immunol 2001; 13:807-16. [PMID: 11369709 DOI: 10.1093/intimm/13.6.807] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The NF-kappaB/Rel transcription factors play an important role in the expression of genes involved in B cell development, differentiation and function. Nuclear NF-kappaB is induced in B cells by engagement of either the BCR or CD40 or by stimulation with lipopolysaccharide (LPS). Despite the importance of NF-kappaB to B cell function, little is known about the signaling pathways leading to NF-kappaB activation. In this report we address the role of phosphoinositide 3'-kinase (PI 3-kinase) in BCR- and LPS-induced NF-kappaB activation using populations of primary murine resting B cells. Using the specific pharmacological inhibitors of PI 3-kinase, Wortmannin and LY294002, we demonstrate that PI 3-kinase activity is vital for BCR-induced NF-kappaB DNA-binding activity. Furthermore, we show that this is achieved via protein kinase C-dependent degradation of IkappaBalpha. Similar analyses reveal that PI 3-kinase is also critical in triggering NF-kappaB DNA-binding activity and IkappaBalpha degradation following LPS stimulation. Interestingly, a PKC inhibitor which blocked the BCR-induced IkappaBalpha degradation had no effect on the degradation of IkappaBalpha after LPS stimulation. Taken together, our results indicate the involvement of PI 3-kinase in at least two distinct signaling pathways leading to activation of NF-kappaB in B cells.
Collapse
Affiliation(s)
- H Bone
- Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, UK
| | | |
Collapse
|
22
|
Yavuzer R, Bone H, Jackson IT. Fronto-orbital fibrous dysplasia. Orbit 2000; 19:119-128. [PMID: 12045956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Fibrous dysplasia, which is characterized by a disorganized mixture of fibrous and osseous elements in the affected bones, is a non-neoplastic developmental anomaly caused by an activating mutation. Despite an identical histological pattern, the clinical behavior varies according to the site of involvement. Fronto-orbital lesions behave more aggressively and generally continue to grow during adulthood. During the last 20 years, 32 cases of fronto-orbital fibrous dysplasia have been treated and the results of treatment have been assessed. The indications for surgery were mainly visual deterioration due to optic nerve compression, globe malposition and widespread disease causing gross facial deformity. The treatment of these patients consisted of radical resection of the fibro-osseous tissue, decompression of the optic nerve canal and reconstruction of the resected fronto-orbital areas with either noninvolved bone grafts or with dysplastic bone which was contoured down or, in one case, heated in the sterilizer. Recently, Pamidronate, a bone resorption inhibitor, has been added to the treatment protocol. During follow-up there have been two recurrences, repeat optic nerve decompression has not been required and overall the esthetic results are satisfactory. Fronto-orbital fibrous dysplasia can have a devastating outcome with high recurrence rates and blindness, especially following incomplete resection. A radical and extensive approach to treatment is recommended; this seems to be the best choice as witnessed by the good results achieved in this series.
Collapse
Affiliation(s)
- Reha Yavuzer
- Institute for Craniofacial and Reconstructive Surgery, Providence Hospital, Southfield, Michigan, United States of America
| | | | | |
Collapse
|
23
|
Greenspan SL, Harris ST, Bone H, Miller PD, Orwoll ES, Watts NB, Rosen CJ. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician 2000; 61:2731-6. [PMID: 10821153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Osteoporosis affects more than 28 million Americans. With the advent of accessible and affordable diagnostic studies, awareness and recognition of this disease by patients and clinicians are growing. Osteoporotic fractures of the spine and hip are costly and associated with significant morbidity and mortality. Over the past decade, a surge of new antiosteoporotic drugs have been labeled or are awaiting labeling by the U.S. Food and Drug Administration. One class of agents used to treat osteoporosis is the bisphosphonates, which inhibit bone resorption, cause an increase in bone mineral density and reduce the risk of future fractures caused by aging, estrogen deficiency and corticosteroid use. Overall, bisphosphonates have been shown to have a strong safety and tolerability profile.
Collapse
Affiliation(s)
- S L Greenspan
- University of Pittsburgh School of Medicine, Pennsylvania, USA
| | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
p46(Shc) and p52(Shc) become heavily tyrosine phosphorylated in response to interleukin 3 (IL-3) treatment. We have investigated the potential of Shc to integrate IL-3 signalling pathways and demonstrate that Shc associates with the beta subunits of the human (betac) and murine (Aic2A) IL-3 receptors, SHIP and Gab2 following IL-3 stimulation. The interaction between Shc and the IL-3 receptor beta chains was direct, mediated by both the SH2 and PTB domains. Interaction with SHIP was via the Shc PTB domain and the Shc SH2 domain mediated the interaction with Gab2. Phosphopeptide competition studies suggest that the SH2 domain interacts primarily with tyrosine 612 of betac (610 of Aic2A), and the PTB domain with tyrosine 577 of betac (575 of Aic2A). PTB binding to IL-3R beta chains was of highest affinity, and appeared to play the primary role in binding. These findings suggest that Shc may play an important role in coordinately integrating IL-3 signalling pathways.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing
- Adaptor Proteins, Vesicular Transport
- Animals
- B-Lymphocytes/drug effects
- B-Lymphocytes/metabolism
- Humans
- Interleukin-3/pharmacology
- Leukemia, Erythroblastic, Acute/pathology
- Mice
- Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases
- Phosphoproteins/metabolism
- Phosphoric Monoester Hydrolases/metabolism
- Phosphorylation
- Proteins/metabolism
- Receptors, Interleukin-3/metabolism
- Shc Signaling Adaptor Proteins
- Signal Transduction/drug effects
- Src Homology 2 Domain-Containing, Transforming Protein 1
- Tumor Cells, Cultured/drug effects
- Tumor Cells, Cultured/metabolism
- Tyrosine/metabolism
- src Homology Domains
Collapse
Affiliation(s)
- H Bone
- Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, UK
| | | |
Collapse
|
25
|
Grauer A, Bone H, McCloskey EV, McClung M, Gutteridge DH, Lyles KW, Mautalen C, Rodan G, Wallach S. Discussion: Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go. J Bone Miner Res 1999; 14 Suppl 2:74-8. [PMID: 10510218 DOI: 10.1002/jbmr.5650140215] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A Grauer
- Institute for Endocrinology and Nuclear Medicine, Frankfurt, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Bone H, Dechert U, Jirik F, Schrader JW, Welham MJ. SHP1 and SHP2 protein-tyrosine phosphatases associate with betac after interleukin-3-induced receptor tyrosine phosphorylation. Identification of potential binding sites and substrates. J Biol Chem 1997; 272:14470-6. [PMID: 9162089 DOI: 10.1074/jbc.272.22.14470] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The cytoplasmic tyrosine phosphatases, SHP1 and SHP2, are implicated in the control of cellular proliferation and survival. Here we demonstrate that both SHP1 and SHP2 associate with the betac subunit of the human interleukin-3 (IL-3) receptor following IL-3 stimulation and that the src homology region 2 (SH2) domains of these phosphatases mediate this interaction. Sequential immunoprecipitation analyses suggest this interaction is direct. Competition studies, using phosphotyrosine-containing peptides based on sequences surrounding key tyrosine residues within betac, suggest that phosphorylation of tyrosine 612 is the key event mediating the association of betac with SHP1 and SHP2. However, inhibition of SHP2 binding to betac, did not prevent tyrosine phosphorylation of SHP2. Interestingly, this same phosphopeptide served as a substrate for the tyrosine phosphatase activity of both SHP1 and SHP2. Binding of these protein-tyrosine phosphatases to the IL-3 receptor may regulate IL-3 signal transduction pathways, both through their catalytic activity and through the recruitment of other molecules to the receptor complex.
Collapse
Affiliation(s)
- H Bone
- School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, United Kingdom
| | | | | | | | | |
Collapse
|
27
|
Welham MJ, Bone H, Levings M, Learmonth L, Wang LM, Leslie KB, Pierce JH, Schrader JW. Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells. J Biol Chem 1997; 272:1377-81. [PMID: 8995447 DOI: 10.1074/jbc.272.2.1377] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Insulin receptor substrate 1 (IRS-1), and its structural relative IRS-2, are both phosphorylated on tyrosine following treatment of cells with interleukin-4 (IL-4) and insulin. We have investigated whether both IRS-1 and IRS-2 are expressed in murine lymphohemopoietic cells. T and B lymphocytes and macrophages from primary cultures expressed only IRS-2, which became phosphorylated on tyrosine following stimulation with both IL-4 and insulin. Likewise, the murine myeloid cell line FD-5 expressed only IRS-2, which was tyrosine phosphorylated in response to IL-4 and insulin, as well as interleukin-3 and granulocyte-macrophage colony stimulating factor. Neither IRS-1 nor IRS-2 were expressed at detectable levels in primary bone marrow mast cells although these cells do respond to IL-4. Moreover, a factor-dependent lymphocyte cell line, CT.4S, which grows continuously in IL-4, did not express detectable levels of IRS-1 or IRS-2. IRS-2 from FD-5 cells stimulated with either IL-4 or insulin bound to glutathione S-transferase fusion proteins of the p85 subunit of phosphoinositol 3'-kinase, Grb2, and Syp, paralleling reported associations of IRS-1 with these molecules and indicating phosphorylation of the corresponding residues on IRS-2.
Collapse
Affiliation(s)
- M J Welham
- The Biomedical Research Centre, University of British Columbia, Vancouver, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Kanis JA, Delmas P, Meunier P, Johnston C, Bonjour J, Christiansen C, Lindsay R, Bone H. The GREES recommendations for the registration of new drugs in the prevention and treatment of osteoporosis. Calcif Tissue Int 1996; 59:410-1. [PMID: 8849411 DOI: 10.1007/s002239900149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
29
|
Bone H, Schenarts P, Fischer S, Booke M, Traber L, Traber D. MODIFIED HEMOGLOBIN REDUCES CATECHOLAMINE REQUIREMENTS IN AN OVINE MODEL OF SEPTIC SHOCK. Shock 1996. [DOI: 10.1097/00024382-199606002-00185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Welham MJ, Learmonth L, Bone H, Schrader JW. Interleukin-13 signal transduction in lymphohemopoietic cells. Similarities and differences in signal transduction with interleukin-4 and insulin. J Biol Chem 1995; 270:12286-96. [PMID: 7744881 DOI: 10.1074/jbc.270.20.12286] [Citation(s) in RCA: 109] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Interleukin-13 (IL-13) and interleukin-4 (IL-4) are related in structure and function and are thought to share a common receptor component. We have investigated the signal transduction pathways activated by these two growth factors, as well as insulin, in cell-lines and primary cells of lymphohemopoietic origin. All three factors induced the tyrosine phosphorylation of a protein of 170 kDa (p170), which coimmunoprecipitated with the p85 subunit of P13'-kinase, via high affinity interactions mediated by the SH2 domains of p85. Antibodies raised against the entire insulin-receptor substrate-1 (IRS-1) protein immunoprecipitated p170 much less efficiently than they did IRS-1 from 3T3 cells. However, antibodies directed against the conserved pleckstrin homology domain of IRS-1 immunoprecipitated both p170 and IRS-1 with similar efficiency, suggesting they share structural similarities in this region. In lymphohemopoietic cells, IL-13, IL-4, and insulin failed to induce increased tyrosine phosphorylation of Shc, or its association with grb2, modification of Sos1, or activation of erk-1 and erk-2 mitogen-activated protein kinases, suggesting that p170 mediates downstream pathways distinct from those mediated by IRS-1. Both IL-13 and IL-4 induced low levels of tyrosine phosphorylation of Tyk-2 and Jak-1. IL-4 also activated the Jak-3-kinase, but, despite other similarities, IL-13 did not. Insulin failed to activate any of the known members of the Janus family of kinases. In that Jak-3 is reported to associate with the IL-2 gamma c chain, these data suggest that the IL-13 receptor does not utilize this subunit. However, both IL-13 and IL-4 induced tyrosine phosphorylation of the IL-4-140 kDa receptor chain, suggesting that this is a component of both receptors in these cells and accounts for the similarities in signaling pathways shared by IL-13 and IL-4.
Collapse
MESH Headings
- 3T3 Cells/metabolism
- Adaptor Proteins, Signal Transducing
- Animals
- Calcium-Calmodulin-Dependent Protein Kinases/metabolism
- Cells, Cultured
- GRB2 Adaptor Protein
- Hematopoietic Stem Cells/drug effects
- Hematopoietic Stem Cells/physiology
- Humans
- Insulin/pharmacology
- Insulin Receptor Substrate Proteins
- Interleukin-13/pharmacology
- Interleukin-13 Receptor alpha1 Subunit
- Interleukin-4/pharmacology
- Janus Kinase 1
- Janus Kinase 3
- Leukemia, Erythroblastic, Acute/pathology
- Lymphocyte Subsets/drug effects
- Lymphocyte Subsets/physiology
- Mice
- Mitogen-Activated Protein Kinase 1
- Mitogen-Activated Protein Kinase 3
- Mitogen-Activated Protein Kinases
- Phosphatidylinositol 3-Kinases
- Phosphoproteins/immunology
- Phosphoproteins/metabolism
- Phosphoproteins/physiology
- Phosphorylation
- Phosphotransferases (Alcohol Group Acceptor)/metabolism
- Plasmacytoma/pathology
- Protein Processing, Post-Translational/drug effects
- Protein Serine-Threonine Kinases/metabolism
- Protein-Tyrosine Kinases/metabolism
- Proteins/genetics
- Proteins/metabolism
- Receptors, Interleukin/drug effects
- Receptors, Interleukin/physiology
- Receptors, Interleukin-13
- Receptors, Interleukin-4
- Recombinant Fusion Proteins/metabolism
- Signal Transduction/drug effects
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- M J Welham
- Biomedical Research Centre, University of British Columbia, Vancouver, Canada
| | | | | | | |
Collapse
|
31
|
|
32
|
D??Acquisto LJ, Bone H, Letner C, Arredondo SH, Langhans G, Takahashi S, Troup JP. 739 PHYSIOLOGICAL RESPONSES TO REDUCED WORKLOAD IN ENDURANCE TRAINED COMPETITIVE SHIMMERS. Med Sci Sports Exerc 1990. [DOI: 10.1249/00005768-199004000-00738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
33
|
Wilson PS, Kleerekoper M, Bone H, Parfitt AM. Urinary total hydroxyproline measured by HPLC: comparison of spot and timed urine collections. Clin Chem 1990; 36:388-9. [PMID: 2302791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- P S Wilson
- Bone and Mineral Research Lab., Henry Ford Hospital, Detroit, MI 48202
| | | | | | | |
Collapse
|
34
|
Affiliation(s)
- P S Wilson
- Bone and Mineral Research Lab., Henry Ford Hospital, Detroit, MI 48202
| | - M Kleerekoper
- Bone and Mineral Research Lab., Henry Ford Hospital, Detroit, MI 48202
| | - H Bone
- Bone and Mineral Research Lab., Henry Ford Hospital, Detroit, MI 48202
| | - A M Parfitt
- Bone and Mineral Research Lab., Henry Ford Hospital, Detroit, MI 48202
| |
Collapse
|
35
|
Kaplan RA, Haussler MR, Deftos LJ, Bone H, Pak CY. The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 1977; 59:756-60. [PMID: 192763 PMCID: PMC372282 DOI: 10.1172/jci108696] [Citation(s) in RCA: 232] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The cuase for the intestinal hyperabsorptionof calcium (Ca) in various forms of hypercalciurias was explored by a careful measurement of plasma 1 alpha, 25-dihydroxycholecalciferol [1 alpha, 25-(OH)I D] and by an assessment of intestinal Ca absorption and of parathyroid function. In 18 cases of primary hyperparathyroidism (PHPT), the mean plasma concentration of 1 alpha, 25-(OH)2D was significantly increased (4.9 +/- 2.2 SD ng/dl vs. 3.4 +/- 0.9 ng/dl for the control group), and was significantly correlated with fractional Ca absorption (alpha) (r = 0.80, P less than 0.001). Plasma 1 alpha, 25-(OH)2D was also correlated with urinary Ca (P less than 0.05), but not with serum Ca or phosphorus (P), P clearance, urinary cyclic AMP, or serum immunoreactive parathyroid hormone. In 21 cases of absorptive hypercalciuria (AH), plasma 1 alpha, 25-(OH)2D was elevated in one-third of cases, and the mean value of 4.5 +/- 1.1 ng/dl was significantly higher than that of the control group (P less than 0.01). Since relative hypoparathyroidism may be present, the normal absolute value of plasma 1 alpha, 25-(OH)2D, found in two-thirds of cases of AH, may be considered to be inappropriately high. Moreover, in the majority of cases of AH, the data points relating plasma 1 alpha, 25-(OH)2D and alpha fell within 95% confidence limits of values found in non-AH groups (including PHPT). The results suggest that the intestinal hyperabsorption of Ca in PHPT aw AH may be vitamin D dependent. However, the disturbance in vitamin D metabolism may not be the sole cause for the high Ca absorption in AH, since in some patients with AH, the intestinal Ca absorption appears to be inapp
Collapse
|
36
|
Abstract
The density of bone in the distal third of the radius was measured in 13 men and 17 women with primary hyperparathyroidism. The bone density was significantly reduced (as compared to age-matched controls) in 7 of 11 postmenopausal women. However, it was reduced in only 2 of 13 men and in 1 of 6 premenopausal women. Thus, most of the postmenopausal women with primary hyperparathyroidism had low bone density, whereas most men and premenopausal women with this condition had normal bone density. The results support the conclusion that oestrogen deficiency may contribute to the development of bone disease by sensitising bone to the action of parathyroid hormone.
Collapse
|
37
|
Abstract
A test was developed to diagnose various forms of hypercalciuria. A two-hour urine sample after an overnight fast and a four-hour urine sample after 1 g of calcium by mouth were tested for calcium, cyclic AMP and creatinine. The 24 patients with absorptive hypercalciuria had normocalcemia and normal fasting urinary calcium (less than 0.11 mg per milligram of urinary creatnine). Urinary calcium was high (greater than or equal to 0.2 mg per milligram of creatinine) after a calcium load. Of the 28 patients with primary hyperparathyroidism (resorptive hypercalciuria), 25 had hypercalcemia and 21 had high fasting urinary calcium. Urinary cyclic AMP, elevated in 30 per cent of fasting patients, was high (greater than 4.60 mu moles per gram of creatinine) in 82 per cent of cases after calcium load. Six patients with renal hypercalciuria had normocalcemia, high fasting urinary calcium, and high (greater than 6.86 mu moles per gram of creatinine) or high-normal fasting urinary cyclic AMP was normal. This simple test should facilitate the differentiation of various causes of hypercalciuria.
Collapse
|